Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates
Authors:
- Nara NetworkNNNara Network
- Laurent PoirelLPLaurent Poirel
- 22 October 2024
- journal article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 31 (1) , 122-124
Abstract
No abstract availableKeywords
Funding Information
- Northwest Advanced Renewables Alliance
- University of Fribourg
This publication has 5 references indexed in Scilit:
- Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2024
- The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States—Is There a Potential Role for Durlobactam?Clinical Infectious Diseases, 2024
- An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam ResistanceOpen Forum Infectious Diseases, 2023
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)Clinical Microbiology and Infection, 2022
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiNature Microbiology, 2017